{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-132736","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.010647+00:00","generated_at":"2026-05-20T03:13:38.034656+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vera Therapeutics atacicept Phase 3 IgAN trial meets primary endpoint; 46% proteinuria reduction","bullets":["Atacicept achieved 46% reduction from baseline in UPCR, 42% vs placebo (p<0.0001) at week 36.","Safety profile favorable and comparable to placebo in the ORIGIN Phase 3 trial of 431 adults.","Vera plans to submit BLA for accelerated approval to FDA in Q4 2025; commercial launch targeted for 2026.","Trial continues blinded to assess eGFR over two years, expected completion in 2027.","No eGFR results shared at this time per FDA guidance; full results to be presented at ASN Kidney Week."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-132736","json":"https://secwatch.observer/filing/0001193125-25-132736.json","markdown":"https://secwatch.observer/filing/0001193125-25-132736.md","text":"https://secwatch.observer/filing/0001193125-25-132736.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000119312525132736/0001193125-25-132736-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000119312525132736/d916346d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T03:13:38.034656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}